13F-HR filed by Lynx1 Capital Management LP
Lynx1 Capital Management LP filed this 13F-HR for the quarter ended 2025-03-31, filed 2025-05-15, with 14 holding rows worth $279,234,734.
- Accession
- 0001892688-25-000120
- Filer
- CIK 1910456
- Filed
- 2025-05-15
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2025
A holdings report, 14 entries on the cover page, a total value of $279,234,734 stated on the cover page (in dollars after the unit check, H1), rows summing to $279,234,734 with VALUE read as dollars as filed, 13F file number 028-22151. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerLynx1 Capital Advisors LLC028-22145
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| GH RESEARCH PLC ORDINARY SHARES | G3855L106 | Stock | 6,443,940 | $71,076,658 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 1,568,841 | $66,032,518 | dollars as filed | |
| PROTAGONIST THERAPEUTICS | 74366E102 | COM | 733,014 | $35,448,557 | dollars as filed | |
| STOKE THERAPEUTICS INC | 86150R107 | COM | 5,291,929 | $35,191,328 | dollars as filed | |
| CULLINAN THERAPEUTICS INC | 230031106 | COM | 3,215,722 | $24,343,016 | dollars as filed | |
| ALLOGENE THERAPEUTICS INC | 019770106 | COM | 11,057,009 | $16,143,233 | dollars as filed | |
| C4 THERAPEUTICS INC | 12529R107 | COM STK | 7,098,133 | $11,357,013 | dollars as filed | |
| Tscan Therapeutics Inc | 89854M101 | COM | 5,357,347 | $7,393,139 | dollars as filed | |
| PRECISION BIOSCIENCES INC | 74019P207 | COM NEW | 766,051 | $3,654,063 | dollars as filed | |
| IBIO INC | 451033708 | CMN | 862,279 | $3,466,362 | dollars as filed | |
| PASSAGE BIO INC | 702712100 | COM | 9,256,953 | $3,268,630 | dollars as filed | |
| UPSTREAM BIO INC | 91678A107 | COMMON STOCK | 219,247 | $1,341,792 | dollars as filed | |
| NEUPHORIA THERAPEUTICS INC | 64136E102 | COM | 45,806 | $263,843 | dollars as filed | |
| DESIGN THERAPEUTICS INC | 25056L103 | COM | 65,954 | $254,582 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001892688-25-000120 | this filing | 2025-05-15 | acceptance time not in the bulk data set |